However, as the PI3K/Akt/mTOR signalling axis is one of the most commonly activated in human cancers, effective targeting of this pathway will remain of high interest to scientists and clinicians in their hunt for improved cancer therapies for patients. This evidence concerns the gene MTOR and cancer.